Marco Schupp

2.2k total citations
17 papers, 175 citations indexed

About

Marco Schupp is a scholar working on Oncology, Pathology and Forensic Medicine and Genetics. According to data from OpenAlex, Marco Schupp has authored 17 papers receiving a total of 175 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 6 papers in Pathology and Forensic Medicine and 4 papers in Genetics. Recurrent topics in Marco Schupp's work include CAR-T cell therapy research (9 papers), Lymphoma Diagnosis and Treatment (6 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Marco Schupp is often cited by papers focused on CAR-T cell therapy research (9 papers), Lymphoma Diagnosis and Treatment (6 papers) and Chronic Lymphocytic Leukemia Research (3 papers). Marco Schupp collaborates with scholars based in United States, Netherlands and United Kingdom. Marco Schupp's co-authors include Veena Shankaran, David Cunningham, Ning Go, Yoon‐Koo Kang, Bogusława Karaszewska, Hui Yang, Hyun Cheol Chung, Eric Van Cutsem, Salvatore Siena and Stefan Knop and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Marco Schupp

15 papers receiving 166 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Marco Schupp United States 8 96 46 43 30 30 17 175
Rie Nakatsuka Japan 9 86 0.9× 76 1.7× 71 1.7× 15 0.5× 14 0.5× 21 240
Burhan Abdullah Zaman Iraq 6 136 1.4× 80 1.7× 25 0.6× 8 0.3× 21 0.7× 14 277
Yakup Ergün Türkiye 7 122 1.3× 30 0.7× 58 1.3× 20 0.7× 12 0.4× 44 181
Rosemary Millen Australia 9 85 0.9× 48 1.0× 29 0.7× 27 0.9× 6 0.2× 15 168
Sanjeev Deva New Zealand 9 179 1.9× 64 1.4× 60 1.4× 19 0.6× 15 0.5× 37 249
Jiashuo Chao China 9 116 1.2× 74 1.6× 45 1.0× 34 1.1× 67 2.2× 20 255
Johan M. van Rooijen Netherlands 8 145 1.5× 37 0.8× 58 1.3× 39 1.3× 11 0.4× 16 224
Arezou Abbasi United States 6 166 1.7× 32 0.7× 33 0.8× 6 0.2× 21 0.7× 12 229
Ephraim Tang Canada 9 226 2.4× 41 0.9× 69 1.6× 25 0.8× 42 1.4× 19 337

Countries citing papers authored by Marco Schupp

Since Specialization
Citations

This map shows the geographic impact of Marco Schupp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marco Schupp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marco Schupp more than expected).

Fields of papers citing papers by Marco Schupp

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marco Schupp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marco Schupp. The network helps show where Marco Schupp may publish in the future.

Co-authorship network of co-authors of Marco Schupp

This figure shows the co-authorship network connecting the top 25 collaborators of Marco Schupp. A scholar is included among the top collaborators of Marco Schupp based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marco Schupp. Marco Schupp is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Ghobadi, Armin, Javier Muñoz, Jason R. Westin, et al.. (2024). Outcomes of subsequent antilymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7. Blood Advances. 8(11). 2982–2990. 4 indexed citations
2.
Locke, Frederick L., Olalekan O. Oluwole, John Kuruvilla, et al.. (2024). Axicabtagene ciloleucel vs standard of care in second-line large B-cell lymphoma: outcomes by metabolic tumor volume. Blood. 143(24). 2464–2473. 14 indexed citations
3.
Filosto, Simone, Saran Vardhanabhuti, Miguel Canales, et al.. (2023). Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7). Blood Cancer Discovery. 5(1). 21–33. 18 indexed citations
4.
Ghobadi, Armin, Javier Muñoz, Jason R. Westin, et al.. (2023). Outcomes of Subsequent Anti-Lymphoma Therapies in Patients (Pts) with Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel (Axi-Cel) or Standard of Care (SOC) in the Second-Line (2L) Zuma-7 Study. Transplantation and Cellular Therapy. 29(2). S371–S372. 1 indexed citations
5.
6.
Westin, Jason R., Caron A. Jacobson, Julio C. Chávez, et al.. (2023). PB2319: ZUMA-23: A GLOBAL, PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD OF CARE AS FIRST-LINE THERAPY IN PATIENTS WITH HIGH-RISK LARGE B-CELL LYMPHOMA. HemaSphere. 7(S3). e3278692–e3278692. 1 indexed citations
7.
Westin, Jason R., Olalekan O. Oluwole, Marie José Kersten, et al.. (2023). PRIMARY OVERALL SURVIVAL ANALYSIS OF THE PHASE 3 RANDOMIZED ZUMA‐7 STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD OF CARE IN RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA. Hematological Oncology. 41(S2). 52–54.
8.
9.
10.
Cutsem, Eric Van, Bogusława Karaszewska, Yoon‐Koo Kang, et al.. (2018). A Multicenter Phase II Study of AMG 337 in Patients with MET-Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma and Other MET-Amplified Solid Tumors. Clinical Cancer Research. 25(8). 2414–2423. 58 indexed citations
11.
Glisson, Bonnie S., Benjamin Besse, Manuel Cobo, et al.. (2017). A Randomized, Placebo-Controlled, Phase 1b/2 Study of Rilotumumab or Ganitumab in Combination With Platinum-Based Chemotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer. Clinical Lung Cancer. 18(6). 615–625.e8. 24 indexed citations
12.
Brown, Jennifer R., Ruth Plummer, Todd M. Bauer, et al.. (2017). Pharmacokinetics of carfilzomib in patients with advanced malignancies and varying degrees of hepatic impairment: an open-label, single-arm, phase 1 study. Experimental Hematology and Oncology. 6(1). 27–27. 8 indexed citations
13.
Berenson, James R., Alan Cartmell, Roger M. Lyons, et al.. (2015). Weekly Carfilzomib with Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma: Updated Results from the Phase 1/2 Study Champion-1 (NCT01677858). Blood. 126(23). 373–373. 3 indexed citations
14.
15.
Schupp, Marco, Justiaan Swanevelder, Giles J. Peek, A Sosnowski, & Tom Spyt. (2003). Postoperative extracorporeal membrane oxygenation for severe intraoperative SIRS 10 h after multiple trauma. British Journal of Anaesthesia. 90(1). 91–94. 8 indexed citations
16.
Schupp, Marco. (2002). Postoperative extracorporeal membrane oxygenation for severe intraoperative SIRS 10 h after multiple trauma. British Journal of Anaesthesia. 90(1). 91–94. 4 indexed citations
17.
Jakob, Andreas, Carsten Bokemeyer, Stefan Knop, et al.. (2002). Capecitabine in patients with breast cancer relapsing after high-dose chemotherapy plus autologous peripheral stem cell transplantation—a phase II study. Anti-Cancer Drugs. 13(4). 405–410. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rie Nakatsuka Breakdown of academic impact, for papers by Burhan Abdullah Zaman Breakdown of academic impact, for papers by Yakup Ergün Breakdown of academic impact, for papers by Rosemary Millen Breakdown of academic impact, for papers by Sanjeev Deva Breakdown of academic impact, for papers by Jiashuo Chao Breakdown of academic impact, for papers by Johan M. van Rooijen Breakdown of academic impact, for papers by Arezou Abbasi Breakdown of academic impact, for papers by Ephraim Tang
Rankless by CCL
2026